Head and Neck Cancer KOL Roundtable NASDAQ: PDSB |

Head and Neck Cancer KOL Roundtable NASDAQ: PDSB | October 26, 2022

Forward Looking Statements Certain information in this presentation may include

forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology

Corporation (the "Company") and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the

Company's management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or

conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," "forecast," "guidance", "outlook" and other similar expressions. Forward-looking

statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as

a result of various factors, including, without limitation: the Company's ability to protect its intellectual property rights; the Company's anticipated capital requirements, including the Company's anticipated cash runway and the Company's

current expectations regarding its plans for future equity financings; the Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that

raising such additional capital may restrict the Company's operations or require the Company to relinquish rights to the Company's technologies or product candidates; the Company's limited operating history in the Company's current line of

business, which makes it difficult to evaluate the Company's prospects, the Company's business plan or the likelihood of the Company's successful implementation of such business plan; the timing for the Company or its partners to initiate the

planned clinical trials for PDS0101, PDS0203 and other Versamune and Infectimune based product candidates; the future success of such trials; the successful implementation of the Company's research and development programs and

collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune and Infectimune based product candidates and the Company's interpretation of the results and findings of such programs and collaborations

and whether such results are sufficient to support the future success of the Company's product candidates; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product

candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund its disclosed clinical trials, which assumes no material changes to our

currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not

necessarily indicative of the final results of the Company's ongoing clinical trials; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action

with respect to, PDS0101, PDS0203 and other Versamune and Infectimune based product candidates; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical

results from its clinical development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company's control, including unforeseen circumstances or

other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read

in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this

press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future

events or otherwise. Versamune is a registered trademark, and Infectimune is a trademark of PDS Biotechnology Corporation.KEYTRUDA is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ,

Disclaimer PDS Biotech is the sponsor of this roundtable Each panelist is

speaking on behalf of PDS Biotech under the terms of a consulting agreement Information presented is consistent with FDA guidelines

Introducing our Panel Dr. Katharine A. Price Co-chair, Head and Neck Disease

Group Mayo Clinic Comprehensive Cancer Center Dr. Neil D. Gross Department of Head and Neck Surgery MD Anderson Dr. Jared Weiss Head and Neck Cancer Section Chief UNC School of Medicine

Today's Agenda 5 Welcome and Introductions Dr. Lauren V. Wood Current

Treatment of Head and Neck Cancer Dr. Neil Gross Unmet Medical Needs in Head and Neck Cancer Dr. Katharine Price PDS0101 for the treatment of HPV16-Positive Head and Neck Cancer Dr. Jared Weiss Panel Discussion Moderated by Dr.

Lauren V. Wood Closing Remarks Dr. Lauren V. Wood

Current Treatment of Head and Neck Cancer Dr. Neil Gross

Head and Neck CancerEpidemiologic Shift Ulysses S. Grant HPV-associated HNSCC

HPV-Positive Head and Neck CancerIncreasing Incidence Tota JE et al. J Clin

HPV-Positive Head and Neck CancerIncreasing Incidence Cancer Statistics,

2022 Siegel, RL CA CANCER J CLIN 2022;72:7-33. https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21708

Head and Neck CancerDifferent Biologic

Behavior 3.2013 7.2014 10.2014 4.2015 6.2015

HPV-Positive Head and Neck CancerCurrent Treatments NCCN Guidelines 2022

HPV-Positive Head and Neck CancerToxicity of Treatment Photographing His Own

Cancer Treatment: A Hell I Wasn't Ready For' New York Times 7.7.2018

HPV-Positive Head and Neck CancerIncreased Focus on Quality of Life (QOL)

Head and Neck CancerDe-escalation Strategies RTOG 1016 Gillison M et al.

Lancet 2019 DART J Clin Oncol 2019 De-ESCALaTE Lancet 2019 J Clin Oncol 2021 Yom SS et al. J Clin Oncol 2021

Recurrent HPV-Positive Head and Neck CancerOpportunity for Improved

Intervention Farhoud F et al. Laryngoscope Investig Otolaryngol 2017 Baseline incidence # Treatment failures Protracted disease Earlier detection HPVctDNA

Unmet Medical Needs in Head and Neck Cancer Dr. Katharine Price

Survival Outcomes for HPV-Positive HNSCC Overall prognosis for HPV-positive

HNSCC is significantly improved compared with HPV-negative HNSCC1 Despite improved cure rates, approximately 20-30% of patients will develop a recurrence after curative intent treatment # involved lymph nodes & T4 tumors significantly

increases risk of recurrence2 1Ang et al., NEJM, 2010, Jul 1;363(1):24-35. 2O'Sullivan et al., Lancet Oncology, Volume 17, Issue 4, April 2016, pages 440-451

Long-term analysis of patients treated with pembrolizumab does not suggest

significant difference in response between patients with HPV-positive and HPV-negative tumors1 Survival Outcomes in the Recurrent/Metastatic Setting Pembrolizumab 1 year OS 2 year OS Median OS (mo) Total 49% 27% 11.6 CPS

1 51% 30% 12.3 CPS 20 57% 38% 14.9 Pembrolizumab + chemotherapy 1 year OS 2 year OS Median OS (mo) Total 53% 29% 13.0 CPS 1 55% 31% 13.6 CPS 20 57% 35% 14.7 KEYNOTE-048 Burtness et al., Lancet 2019, Vol 394,

issue 10212, p1915-1928 1Mehra et al., Br J Cancer 119, 153-159 (2018).

No Improvement in Progression Free Survival (PFS) with Pembrolizumab Alone or

with Chemotherapy Burtness et al., Lancet, 2019

Changing of Face of Patients with HNSCC Younger patient

population Predominantly male Less tobacco and alcohol use Fewer comorbidities

Better QOL with Immunotherapy Compared with Chemotherapy Ferris et al., N Engl

J Med 2016;375:1856-67

Unmet Needs for Patients with Recurrent/Metastatic HPV-Positive HNSCC Curative

treatments Improved therapies allowing patients to live longer with their disease with good QOL Better immunotherapy-based treatments to delay need for cytotoxic chemotherapy Preservation of QOL and function while on treatment

Prevention is the Best Cure of All

PDS0101 for the Potential Treatment of HPV16-Positive Head and Neck Cancer Dr.

Phase 2: PDS0101 in Combination with KEYTRUDA For the potential treatment of

HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002)

Complete Response (CR) Partial Response (PR) Stable Disease (SD) Progressive

Disease (PD) N=17 Subjects w/Imaging Data OR (2 CR + 5PR) 7 (41.2%) SD (reduction in 4/6) 6 (35.3%) PD 4 (23.5%) CR+PR+SD 13 (76.5%) * * * * * * * Indicates CPS>20 All others CPS 1-19 Phase 2: PDS0101 in Combination with

KEYTRUDA For the potential treatment of HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002)

Treatment Emergent Adverse Events (TEAEs) Safety Population (N=19) CPI Na ve

Subjects (N=19) N (%) : Events Subjects with any TEAEs Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 18 (94.7%) : 371 3 (15.8%) : 3038 (42,1%) : 51 5 (26.3%) : 110 (0.0%) : 4 2 (10.5%) : 2 Grade 3 TEAEs Attributed to Study Treatment

by Investigator No subjects met this criteria 0 Grade 3 & 4 Treatment Related TEAEs No subjects met this criteria 0 At 9 Months of Follow Up (Median PFS not yet Achieved) % of Patients Alive at Median 9 Months 89% Progression

Free Survival Rate (PSF) 55.2% Overall Survival Rate (OS) 87.2% Phase 2: PDS0101 in Combination with KEYTRUDA For the potential treatment of HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002)

Closing Remarks Dr. Lauren V. Wood